Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease

Cardiovascular Intervention and Therapeutics

Volumn 29, Issue 4, 2014, Pages 324-333

  Hiasa, Y ^a   Teng, R ^b   Emanuelsson, H ^c  

^a TOKUSHIMA RED CROSS HOSPITAL   (Japan)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Japanese; P2Y12 receptor antagonist; Pharmacodynamics; Pharmacokinetics; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; AR C124910XX; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ABDOMINAL DISCOMFORT; ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASIAN; BLEEDING; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; LIP CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MOUTH CANCER; MULTICENTER STUDY; PARALLEL DESIGN; PERCUTANEOUS CORONARY INTERVENTION; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THROMBOCYTE AGGREGATION INHIBITION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URTICARIA; VERY ELDERLY; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADENOSINE; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; YOUNG ADULT;

EID: 84919662580     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-014-0277-1     Document Type: Article

References (22)

1. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.
2. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemostas. 2009;7:1556–65.
3. (12) inhibitor ticagrelor in acute coronary syndromes. Postgrad Med. 2011;123:79–90.
4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
5. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70:65–77.
6. 12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects. Can J Clin Pharmacol. 2010;15:e426.
7. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487–96.
8. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514–21.
9. Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug–drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos. 2011;39:703–10.
10. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85.
11. Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci. 2013;123:143–54.
12. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.
13. Roden DM, Stein CM. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation. 2009;119:2127–30.
14. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation. 2012;125:584–91.
15. Teng R, Butler K. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of ticagrelor in healthy Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther. 2013 [Epub ahead of print].
16. Labarthe J, Théroux P, Angioï M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol. 2005;46:638–45.
17. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2299–306.
18. 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet Inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599–605.
19. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
20. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J. 2009;73:336–42.
21. Yokoi H, Kimura T, Isshiki T, Ogawa H, Ikeda Y. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thromb Res. 2012;129:623–8.
22. Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single- and multiple-doses of ticagrelor in healthy Chinese volunteers. Clin Drug Investig. 2012;32:87–97.